Roche, world’s largest biotech company with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, diseases of the central nervous system including in vitro diagnostics and tissue-based cancer diagnostics, on July 23, announced that its Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low and middle income country programs where the disease burden is the highest.
The
expansion of the Global Access Program highlights Roche’s commitment to improve
access to cost-effective resources, implement scale-up programs, and contribute
to the elimination of diseases in the regions with the greatest need.
A statement by African Media Agency, made available to OpenLife, says “With
effective treatment options for these infectious agents and improved patients
access to diagnostics, early detection can help save lives and ease
suffering,” said Michael Heuer, CEO Roche Diagnostics. “As the leader
in infectious disease diagnosis testing, Roche is dedicated to support goals on
eradicating diseases globally.”
“Access to cutting-edge, best in class diagnostic test results means more
patients being appropriately diagnosed and well treated, resulting in lives
saved,” stated Clinton Health Access Initiative’s (CHAI’s) Chief Science
Officer David Ripin. “We welcome Roche’s decision to expand access to
tests for hepatitis, tuberculosis, and HPV (the leading cause of cervical
cancer) to their Global Access Program, providing health systems with
transparent and consistent pricing to these important tests in addition to the
HIV viral load and early infant diagnostics already established in the program.
CHAI values Roche’s continued partnership in the effort to make diagnostics
seamlessly available in well optimized diagnostic lab systems throughout the
world.”
“Accessible pricing can be the difference between a patient getting a
quality diagnosis or not,” said Catharina Boehme, CEO of the Foundation
for Innovative New Diagnostics (FIND) – a global non-profit devoted to the
development and delivery of diagnostics for diseases that include TB and HCV.
“FIND is proud to have worked with Roche to expand the Global Access
Program for these deadly diseases, leveraging our support for its TB
assay.”
Access to screening, early detection and prevention of transmission reduces the
spread of disease. Tuberculosis is a major health crisis and is the leading
cause of infectious disease deaths worldwide. Access to hepatitis diagnostic
tests for HBV and HCV will improve the outlook of eliminating these chronic
infections. And screening with HPV DNA testing can more accurately identify
women at risk for cervical cancer than other screening methods . With
vaccination and proper screening, cervical cancer is a preventable disease .
Importantly, infection with HPV has been found to increase the risk of HIV
transmission for both men and women. Similarly, women living with HIV are four
to 10 times more likely to develop cervical cancer. Screening for co-infection
(HIV+ HPV) can significantly improve disease management decisions and enable
appropriate patient care.
In total, the Global Access Program now includes molecular diagnostics for
HIV-1 viral load, HIV-1 and HIV-2 early infant diagnosis, the cobas® Plasma
Separation Card – an innovative plasma collection device, MTB and MTB –
RIF/INH, Hepatitis B and C, and Human Papillomavirus. All these assays run on
the cobas® 4800/6800/8800 platforms for various testing volume needs enabled by
the cobas® Plasma Separation Card that transports samples from remote
areas/sites to the central lab for further processing.
About Author
